New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist
| Autor: | A.T.A. Fazekas, J.M. Husson, André Dupont, Bélanger A, Fernand Labrie, Jean-Pierre Raynaud, F. A. Lefebvre, Lionel Cusan |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Male
endocrine system medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Gonadotropin-releasing hormone urologic and male genital diseases Antiandrogen Imidazolidines Buserelin Gonadotropin-Releasing Hormone Prostate cancer Endocrinology Prostate Internal medicine Testis medicine Animals Humans Gonadal Steroid Hormones Testosterone business.industry Imidazoles Prostatic Neoplasms Androgen Antagonists medicine.disease Rats Androgen receptor medicine.anatomical_structure Hormonal therapy Drug Therapy Combination business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Hormone research. 18(1-3) |
| ISSN: | 0301-0163 |
| Popis: | Treatment with an LHRH agonist (HOE-766) alone causes an almost complete blockage of testicular testosterone formation in rat and man. In order to neutralize androgens of adrenal origin, a pure antiandrogen (RU-23908) was given in combination with the LHRH agonist in the rat. At doses where each drug has no or minimal effect alone, prostate and seminal vesicle weight were reduced to 9 and 15% of control after 5 months of combined treatment, respectively. Among the species studied, man is the most sensitive to the inhibitory effect of treatment with LHRH agonists on testicular steroidogenesis. Near castration levels of serum testosterone and 5 alpha-dihydrotestosterone are obtained within 1-2 weeks of daily subcutaneous administration of the LHRH agonist [D-Ser(tbu)6, des-Gly-NH2(10)]LHRH ethylamide (HOE-766) in adult men with cancer of prostate. The decrease in serum androgen levels is accompanied by objective remission of the cancer in approximately 75% of cases. In a preliminary study where the LHRH agonist was administered in combination with the pure antiandrogen RU-23908, it was shown that the antiandrogen does not interfere with the LHRH-induced inhibition of serum androgen levels. The ease of application of this new form of hormonal therapy should permit its use at early stages of the disease and thus reduce the development of metastases and androgen-resistant cell clones. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|